Module 1 of 5
Measuring skin disease
How skin disease is measured in trials: area, global assessments, responder endpoints and patient reports.
Lecture for Module 1. Open the playlist on YouTube
Key points
- The area of one hand is about 1 percent of body surface area (EMA psoriasis guideline).
- An IGA rates overall severity on a defined ordinal scale; vIGA-AD runs 0 (clear) to 4 (severe) (Simpson 2020).
- A static assessment rates the disease at the visit, without reference to baseline.
- A responder endpoint such as EASI-75 is a binary outcome against a prespecified threshold.
- A PRO comes directly from the patient, without interpretation by anyone else (FDA PRO guidance).
- The MCID is the smallest change patients perceive as meaningful (Basra 2015).
Reading for this module
- Simpson et al., J Am Acad Dermatol 2020 (vIGA-AD)The validated IGA for atopic dermatitis.
- FDA guidance, Patient-Reported Outcome Measures (2009)Definition and use of PROs to support labeling.
- EMA guideline on psoriasis medicinesBSA estimation and static global assessments.
Module 1 quiz
10 questions. Pass mark: 9 of 10. Questions and answers are shuffled each time, and you see the explanations when you finish.